All In Biotech

Drug Trial Radar · NCT06661720

Testing the Addition of the Anti-Cancer Drug Tivozanib to Immunotherapy (Pembrolizumab) After Surgery to Remove All Known Sites of Kidney Cancer

Short TeRm Intensified Pembrolizumab (KEytruda) and Tivozanib for High-Risk Renal Cell Carcinoma - STRIKE

Last checked: Nov 19, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 1,040 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

1,040

Planned (sponsor's estimate)

Start

Mar 14, 2025

Primary completion

Nov 2037

Study completion Nov 2037

Sponsor

Lead sponsor
Alliance for Clinical Trials in OncologyAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Oct 28, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This phase III trial compares the effect of adding tivozanib to standard therapy pembrolizumab versus pembrolizumab alone for the treatment of patients with high-risk renal cell carcinoma (RCC). Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Tivozanib is in a class of medications called kinase inhibitors. It works by blocking the action of the abnormal protein that signals tumor cells to multiply. This helps stop the spread of tumor cells. Giving pembrolizumab and tivozanib together may work better than pembrolizumab alone in treating patients with RCC.

Conditions

  • Clear Cell Renal Cell Carcinoma
  • Renal Cell Carcinoma (RCC)
  • Stage II Renal Pelvis Cancer AJCC v8
  • Stage III Renal Pelvis Cancer AJCC v8

Interventions

  • PembrolizumabBiological

    Given intravenously

  • TivozanibDrug

    Given orally

  • Biospecimen CollectionProcedure

    Undergo blood sample collection

  • MRIProcedure

    Undergo MRI

  • Computed TomographyProcedure

    Undergo CT scan

  • BiopsyProcedure

    Undergo biopsy

  • Questionnaire AdministrationOther

    Ancillary studies

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Disease-free survival (DFS)Time frame: From time of randomization until disease recurrence or death, assessed up to 10 years

Locations

429 sites in 1 country. Site status is shown where the registry gives one.

  • Cancer Center at Saint Joseph's

    Phoenix, Arizona · Active not recruiting

  • Banner University Medical Center - Tucson

    Tucson, Arizona · Recruiting

  • University of Arizona Cancer Center-North Campus

    Tucson, Arizona · Recruiting

  • NEA Baptist Memorial Hospital and Fowler Family Cancer Center - Jonesboro

    Jonesboro, Arkansas · Recruiting

  • University of Arkansas for Medical Sciences

    Little Rock, Arkansas · Recruiting

  • Sutter Auburn Faith Hospital

    Auburn, California · Recruiting

  • Tower Cancer Research Foundation

    Beverly Hills, California · Recruiting

  • City of Hope Comprehensive Cancer Center

    Duarte, California · Recruiting

  • UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care

    Irvine, California · Recruiting

  • City of Hope at Irvine Lennar

    Irvine, California · Recruiting

  • UC San Diego Moores Cancer Center

    La Jolla, California · Recruiting

  • City of Hope Antelope Valley

    Lancaster, California · Recruiting

  • Los Angeles General Medical Center

    Los Angeles, California · Recruiting

  • USC / Norris Comprehensive Cancer Center

    Los Angeles, California · Recruiting

  • Cedars-Sinai Medical Center

    Los Angeles, California · Recruiting

  • UCLA / Jonsson Comprehensive Cancer Center

    Los Angeles, California · Recruiting

  • Memorial Medical Center

    Modesto, California · Recruiting

  • USC Norris Oncology/Hematology-Newport Beach

    Newport Beach, California · Recruiting

  • UC Irvine Health/Chao Family Comprehensive Cancer Center

    Orange, California · Recruiting

  • Palo Alto Medical Foundation Health Care

    Palo Alto, California · Recruiting

  • Sutter Roseville Medical Center

    Roseville, California · Recruiting

  • Sutter Medical Center Sacramento

    Sacramento, California · Recruiting

  • University of California Davis Comprehensive Cancer Center

    Sacramento, California · Recruiting

  • UC San Diego Medical Center - Hillcrest

    San Diego, California · Recruiting

  • California Pacific Medical Center-Pacific Campus

    San Francisco, California · Recruiting

  • Mills Health Center

    San Mateo, California · Recruiting

  • Palo Alto Medical Foundation-Santa Cruz

    Santa Cruz, California · Recruiting

  • Palo Alto Medical Foundation-Sunnyvale

    Sunnyvale, California · Recruiting

  • City of Hope South Bay

    Torrance, California · Recruiting

  • Torrance Memorial Physician Network - Cancer Care

    Torrance, California · Recruiting

  • City of Hope Upland

    Upland, California · Recruiting

  • Sutter Solano Medical Center/Cancer Center

    Vallejo, California · Recruiting

  • UCHealth University of Colorado Hospital

    Aurora, Colorado · Recruiting

  • UCHealth Memorial Hospital Central

    Colorado Springs, Colorado · Recruiting

  • Memorial Hospital North

    Colorado Springs, Colorado · Recruiting

  • UCHealth - Cherry Creek

    Denver, Colorado · Recruiting

  • Poudre Valley Hospital

    Fort Collins, Colorado · Recruiting

  • Cancer Care and Hematology-Fort Collins

    Fort Collins, Colorado · Recruiting

  • UCHealth Greeley Hospital

    Greeley, Colorado · Recruiting

  • UCHealth Highlands Ranch Hospital

    Highlands Ranch, Colorado · Recruiting

Showing 40 of 429 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.